PharmaVentures has announced its new office in Korea as part of its continued strategic expansion. Headquartered in London, UK, PharmaVentures has been assisting Korean biopharma companies for more than 5 years on various transaction and strategy projects. JungHyun Eom, Associate, is now based in Seoul, South Korea, to support current and prospective clients in the emerging Korean biotech sector.

South Korea is recognised globally as a leading nation for innovation. Western pharma companies are increasingly turning their attention to the rapidly expanding biotech sector there. PharmaVentures has successfully acted as the bridge between Western pharma and Korean biotech innovators on over 40 transactional projects.

The company has 4 bilingual Korean speakers with strong scientific/technical background. Leveraging over 30 years of experience in the global biopharma deal making scene, PharmaVentures has helped Korean companies to meet their strategic objectives by connecting the Korean and Western Biopharma industries through licensing and M&A deals.

Over the past 5 years, PharmaVentures has been collaborating with several Korean government institutions such as SEOUL BIOHUB, Korea Health Industry Development Institute (KHIDI) and Korea Drug Development Fund (KDDF) to provide educational and thought leadership activities, working towards globalising the Korean biopharma industry.

PharmaVentures has signed a Memorandum of Understanding (MoU) with Shinhan Investment Corp to collaborate closely to provide a broader range of capabilities and services to both Korean biotech companies and global biopharma companies looking at Korean biotech opportunities.